drugset
drugset / Trial / NCT03456388

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects

NCT03456388 ↗

Phase 1 Completed 58 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the safety, tolerability and pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Chinese heathy subjects. Part of the participants will receive Ammoxetine Hydrochloride Enteric-coated Tablets, while the other part will receive placebo.

Timeline

Start
2017-10-30
Primary completion
2018-07-11
Completion
2019-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Ammoxetine Unknown 2.5 mg —
Subject Ammoxetine Unknown 7.5 mg —
Subject Ammoxetine Unknown 15 mg —
Subject Ammoxetine Unknown 30 mg —
Subject Ammoxetine Unknown 45 mg —
Subject Ammoxetine Unknown 65 mg —
Subject Ammoxetine Unknown 100 mg —

Indications

depressive disorder